What is it about?
The meta-analysis indicated that plasma ESR1 mutation assessment may have prognostic signifcance and clinical value in guiding further endocrine therapy choice in ER+ MBC patients who received prior AI therapy.
Featured Image
Why is it important?
our results suggest that plasma ESR1 mutation analysis may have prognostic value and clinical implication in directing further endocrine therapy choice in ER+ MBC patients who failed prior treatment with AIs.
Read the Original
This page is a summary of: Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis, Cancer Management and Research, August 2018, Dove Medical Press,
DOI: 10.2147/cmar.s173193.
You can read the full text:
Resources
Contributors
The following have contributed to this page
